Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis

BackgroundTo systematically assess the prevalence of BRCA1 and BRCA2 gene mutations in women with Hereditary Breast and/or Ovarian Cancer (HBOC) in Arab countries and to describe the variability in the BRCA gene mutations in different regions of the Arab world.MethodsObservational studies reporting prevalence of BRCA mutations from 22 Arab countries were systematically searched in databases including PUBMED, EMBASE, Web of Science, and Google Scholar. Two reviewers independently screened the studies and extracted data and assessed the risk of bias. Hoy’s risk of Bias tool was used to assess the biases in individual studies. Due to substantial heterogeneity, pooled weighted estimates were calculated using Quality Effect Models (QEM) that adjust for bias, while the Random Effect Models (REM) estimates served as the sensitivity estimates.ResultsFourteen studies reporting prevalence of BRCA were included. The pooled estimate of BRCA among HBOC was 20% (95% CI: 7–36%). Subgroup analysis including only those with low risk of bias provided an estimate of 11% (95% CI: 1–27%). Levant region had higher prevalence 28% (95% CI: 11–49%) compared to Arabian Gulf region and North Africa but differences are not statistically significant, when tested using Z-test for proportions.ConclusionGiven the pooled estimates vary widely with substantial heterogeneity, larger, well-designed studies are warranted to better understand the frequency and the impact of BRCA gene mutations among Arab women.Trial registrationInternational Prospective Register of Systematic Reviews (PROSPERO) registration number: CRD42018095905.

[1]  Tumor characteristics and prognosis in familial breast cancer , 2016, BMC Cancer.

[2]  M. Castiglione,et al.  BRCA in breast cancer: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  L. Fritschi,et al.  Breast cancer among Yemeni women using the National Oncology Centre Registry 2004-2010. , 2012, Cancer epidemiology.

[4]  E. Hafez,et al.  Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection , 2010, Journal of experimental & clinical cancer research : CR.

[5]  A. Benider,et al.  BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants. , 2012, Gynecologic oncology.

[6]  P B Herdson,et al.  Ethnic differences. , 1990, The New Zealand medical journal.

[7]  F. Jamali,et al.  BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer. , 2015, The oncologist.

[8]  R. Scully,et al.  Hereditary breast and ovarian cancer genes. , 2003, Methods in molecular biology.

[9]  F. Blyth,et al.  Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. , 2012, Journal of clinical epidemiology.

[10]  Ethnic differences in cancer risk resulting from genetic variation , 1999, Cancer.

[11]  A. Toss,et al.  Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes , 2015, BioMed research international.

[12]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[13]  B. Arun,et al.  Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan , 2018, BMC Cancer.

[14]  A. Sutton,et al.  In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. , 2014, Journal of clinical epidemiology.

[15]  D. Bercovich,et al.  A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer , 2007, BMC Cancer.

[16]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[17]  David Moher,et al.  Meta-analysis of Observational Studies in Epidemiology , 2000 .

[18]  Douglas G. Altman,et al.  Analysing Data and Undertaking Meta‐Analyses , 2019 .

[19]  A. Ashworth,et al.  Family history and risk of breast cancer: an analysis accounting for family structure , 2017, Breast Cancer Research and Treatment.

[20]  K. Al-Kuraya,et al.  Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis , 2016, International journal of cancer.

[21]  U. Hamann,et al.  Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany , 2003, European Journal of Human Genetics.

[22]  Rajvir Singh,et al.  Arab women's breast cancer screening practices: a literature review. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[23]  Aouatef Riahi,et al.  Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families , 2017, Breast Cancer.

[24]  S. Ahmed,et al.  Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population , 2011, Molecular Biology Reports.

[25]  M. Al-Kuwari,et al.  Perceptions of Arab men regarding female breast cancer screening examinations—Findings from a Middle East study , 2017, PloS one.

[26]  B. Ward,et al.  BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast‐ovarian cancer , 2009, Cancer.

[27]  M. Pinfari.  League of Arab States , 2015 .

[28]  H. Bugrein,et al.  Genotype and Phenotype Correlation of Breast Cancer in BRCA MutationCarriers and Non-Carriers , 2015 .

[29]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[30]  Lotfi Chouchane,et al.  Breast cancer in Arab populations: molecular characteristics and disease management implications. , 2013, The Lancet. Oncology.

[31]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[32]  Y. Miki,et al.  Cross‐sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer , 2008, Cancer science.

[33]  A. Godwin,et al.  Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing , 2014, Breast Cancer Research and Treatment.

[34]  Douglas G. Altman,et al.  Chapter 9: Analysing Data and Undertaking Meta-Analyses , 2008 .

[35]  E. Chouery,et al.  Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon , 2012, Hereditary cancer in clinical practice.

[36]  Å. Borg,et al.  Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. , 2001, Journal of the National Cancer Institute.

[37]  W. Han,et al.  The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study , 2012, Familial Cancer.

[38]  D. Mukherji,et al.  Anxiety, Depression and Quality of Life in Breast Cancer Patients in the Levant , 2017, Asian Pacific journal of cancer prevention : APJCP.

[39]  B. Park,et al.  High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients , 2018, Breast Cancer Research and Treatment.

[40]  Y. Bignon,et al.  BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases , 2008, International Journal of Medical Sciences.

[41]  L. Bouguenouch,et al.  High frequency of the recurrent c.1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast–ovarian cancer prevention and control , 2017, BMC Research Notes.

[42]  Y. Bignon,et al.  Mutation Screening of the BRCA1 Gene in Early Onset and Familial Breast/Ovarian Cancer in Moroccan Population , 2012, International journal of medical sciences.

[43]  M. Larsen,et al.  Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics , 2014, Breast cancer : basic and clinical research.

[44]  I. Gupta,et al.  Molecular genetics complexity impeding research progress in breast and ovarian cancers , 2017, Molecular and clinical oncology.

[45]  Suhail A R Doi,et al.  A Quality-Effects Model for Meta-Analysis , 2008, Epidemiology.

[46]  G. Hamadeh,et al.  Sociological Transition and Breast Cancer in the Arab World: the Experience of Lebanon , 2017, Asian Pacific journal of cancer prevention : APJCP.